Andreas Tebbe
YOU?
Author Swipe
View article: Supplementary Figure 2 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist
Supplementary Figure 2 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist Open
PDF file - 269K, Effect of RG7356 on p-MEK1/2 signal in MDA-MB 231 xenografts
View article: Supplementary Table 1 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist
Supplementary Table 1 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist Open
XLS file - 3.5M, Phosphoproteomics Raw Data
View article: Supplementary Figure 4 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist
Supplementary Figure 4 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist Open
PDF file - 105K, Background optimization of p-ERK1/2-ELISA by use of alternative blocking buffers
View article: Supplementary Figure 4 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist
Supplementary Figure 4 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist Open
PDF file - 105K, Background optimization of p-ERK1/2-ELISA by use of alternative blocking buffers
View article: Data from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist
Data from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist Open
The cell surface glycoprotein CD44 plays an important role in the development and progression of various tumor types. RG7356 is a humanized antibody targeting the constant region of CD44 that shows antitumor efficacy in mice implanted with…
View article: Supplementary Table 1 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist
Supplementary Table 1 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist Open
XLS file - 3.5M, Phosphoproteomics Raw Data
View article: Supplementary Figure 1 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist
Supplementary Figure 1 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist Open
PDF file - 490K, Overview of regulated phosphoprotein networks after 4.5h anti-CD44 treatment compared to the vehicle control
View article: Data from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist
Data from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist Open
The cell surface glycoprotein CD44 plays an important role in the development and progression of various tumor types. RG7356 is a humanized antibody targeting the constant region of CD44 that shows antitumor efficacy in mice implanted with…
View article: Supplementary Figure 1 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist
Supplementary Figure 1 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist Open
PDF file - 490K, Overview of regulated phosphoprotein networks after 4.5h anti-CD44 treatment compared to the vehicle control
View article: Supplementary Figure 3 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist
Supplementary Figure 3 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist Open
PDF file - 336K, No modulation of signaling in PL45 xenografts after RG7356 treatment
View article: Supplementary Figure 3 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist
Supplementary Figure 3 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist Open
PDF file - 336K, No modulation of signaling in PL45 xenografts after RG7356 treatment
View article: Supplementary Figure 2 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist
Supplementary Figure 2 from Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 Antagonist Open
PDF file - 269K, Effect of RG7356 on p-MEK1/2 signal in MDA-MB 231 xenografts
View article: SAT-118 COMPARATIVE TRANSCRIPTOMIC ANALYSIS OF CULTURED PODOCYTES AND HUMAN KIDNEY ORGANOIDS AT SINGLE-CELL RESOLUTION
SAT-118 COMPARATIVE TRANSCRIPTOMIC ANALYSIS OF CULTURED PODOCYTES AND HUMAN KIDNEY ORGANOIDS AT SINGLE-CELL RESOLUTION Open
Podocytes are terminally differentiated kidney cells that are vital to kidney filter function. Podocyte injury and loss is central to the pathogenesis of proteinuric kidney diseases. Conditionally-immortalized differentiated mouse podocyte…
View article: SUN-212 THE KIDNEY GENOME ATLAS: A WHOLE GENOME LANDSCAPE OF 5,800 INDIVIDUALS PROVIDES UNPRECEDENTED INSIGHTS INTO THE MOLECULAR MECHANISMS OF PROGRESSIVE KIDNEY DISEASES
SUN-212 THE KIDNEY GENOME ATLAS: A WHOLE GENOME LANDSCAPE OF 5,800 INDIVIDUALS PROVIDES UNPRECEDENTED INSIGHTS INTO THE MOLECULAR MECHANISMS OF PROGRESSIVE KIDNEY DISEASES Open
Chronic kidney disease (CKD) is a heterogeneous disorder affecting more than 30 million people in the US. Despite the urgent need for targeted therapeutics, the mechanistic basis of CKD including the genetic variants that drive it has rema…
View article: Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial
Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial Open
Human protein biomarker discovery relies heavily on pre-clinical models, in particular established cell lines and patient-derived xenografts, but confirmation studies in primary tissue are essential to demonstrate clinical relevance. We de…
View article: Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells
Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells Open
View article: Integrated genomics and proteomics define huntingtin CAG length–dependent networks in mice
Integrated genomics and proteomics define huntingtin CAG length–dependent networks in mice Open